Literature DB >> 26180941

Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis.

Sébastien Héritier1, Mathilde Jehanne2, Guy Leverger1, Jean-François Emile3, Jean-Claude Alvarez4, Julien Haroche5, Jean Donadieu1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26180941     DOI： 10.1001/jamaoncol.2015.0736

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  30 in total

1.  Langerhans cell histiocytosis presenting as Crohn's disease: a case report.

Authors:  Amelie Therrien; Zaki El Haffaf; Claire Wartelle-Bladou; Justin Côté-Daigneault; Bich N Nguyen
Journal:  Int J Colorectal Dis       Date:  2018-05-08       Impact factor: 2.571

2.  Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes.

Authors:  Lynn H Lee; Anjelika Gasilina; Jayeeta Roychoudhury; Jason Clark; Francis X McCormack; Joseph Pressey; Michael S Grimley; Robert Lorsbach; Siraj Ali; Mark Bailey; Philip Stephens; Jeffrey S Ross; Vincent A Miller; Nicolas N Nassar; Ashish R Kumar
Journal:  JCI Insight       Date:  2017-02-09

Review 3.  Histiocytic neoplasms in the era of personalized genomic medicine.

Authors:  Benjamin H Durham; Eli L Diamond; Omar Abdel-Wahab
Journal:  Curr Opin Hematol       Date:  2016-07       Impact factor: 3.284

4.  Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition.

Authors:  Olive S Eckstein; Johannes Visser; Carlos Rodriguez-Galindo; Carl E Allen
Journal:  Blood       Date:  2019-02-04       Impact factor: 22.113

Review 5.  Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.

Authors:  Matthias Papo; Fleur Cohen-Aubart; Ludovic Trefond; Adeline Bauvois; Zahir Amoura; Jean-François Emile; Julien Haroche
Journal:  Curr Oncol Rep       Date:  2019-05-21       Impact factor: 5.075

Review 6.  Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages.

Authors:  Jean-François Emile; Oussama Abla; Sylvie Fraitag; Annacarin Horne; Julien Haroche; Jean Donadieu; Luis Requena-Caballero; Michael B Jordan; Omar Abdel-Wahab; Carl E Allen; Frédéric Charlotte; Eli L Diamond; R Maarten Egeler; Alain Fischer; Juana Gil Herrera; Jan-Inge Henter; Filip Janku; Miriam Merad; Jennifer Picarsic; Carlos Rodriguez-Galindo; Barret J Rollins; Abdellatif Tazi; Robert Vassallo; Lawrence M Weiss
Journal:  Blood       Date:  2016-03-10       Impact factor: 22.113

7.  Targeted inhibition of the MAPK pathway: emerging salvage option for progressive life-threatening multisystem LCH.

Authors:  Alexandra Kolenová; Raphaela Schwentner; Gunhild Jug; Ingrid Simonitsch-Klupp; Christoph Kornauth; Lukáš Plank; Júlia Horáková; Ivana Bodová; Tomáš Sýkora; Lucia Geczová; Wolfgang Holter; Milen Minkov; Caroline Hutter
Journal:  Blood Adv       Date:  2017-02-02

8.  Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial.

Authors:  Carl E Allen; Theodore W Laetsch; Rajen Mody; Meredith S Irwin; Megan S Lim; Peter C Adamson; Nita L Seibel; D Williams Parsons; Y Jae Cho; Katherine Janeway
Journal:  J Natl Cancer Inst       Date:  2017-05-01       Impact factor: 13.506

9.  Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells.

Authors:  Benjamin H Durham; Damien Roos-Weil; Claude Baillou; Fleur Cohen-Aubart; Akihide Yoshimi; Makoto Miyara; Matthias Papo; Zofia Hélias-Rodzewicz; Nathalie Terrones; Neval Ozkaya; Ahmet Dogan; Raajit Rampal; Fanny Urbain; Lucie Le Fèvre; Eli L Diamond; Christopher Y Park; Thomas Papo; Frédéric Charlotte; Guy Gorochov; Valérie Taly; Olivier A Bernard; Zahir Amoura; Omar Abdel-Wahab; François M Lemoine; Julien Haroche; Jean-François Emile
Journal:  Blood       Date:  2017-05-31       Impact factor: 22.113

10.  Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.

Authors:  Eli L Diamond; Benjamin H Durham; Julien Haroche; Zhan Yao; Jing Ma; Sameer A Parikh; Zhaoming Wang; John Choi; Eunhee Kim; Fleur Cohen-Aubart; Stanley Chun-Wei Lee; Yijun Gao; Jean-Baptiste Micol; Patrick Campbell; Michael P Walsh; Brooke Sylvester; Igor Dolgalev; Olga Aminova; Adriana Heguy; Paul Zappile; Joy Nakitandwe; Chezi Ganzel; James D Dalton; David W Ellison; Juvianee Estrada-Veras; Mario Lacouture; William A Gahl; Philip J Stephens; Vincent A Miller; Jeffrey S Ross; Siraj M Ali; Samuel R Briggs; Omotayo Fasan; Jared Block; Sebastien Héritier; Jean Donadieu; David B Solit; David M Hyman; José Baselga; Filip Janku; Barry S Taylor; Christopher Y Park; Zahir Amoura; Ahmet Dogan; Jean-Francois Emile; Neal Rosen; Tanja A Gruber; Omar Abdel-Wahab
Journal:  Cancer Discov       Date:  2015-11-13       Impact factor: 39.397
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.